21
藥劑科實習生:黃中成 指導老師:蘇蜂琪藥師 2014.08.13 Osteoporosis

Osteoporosis - CGMH · Osteoporosis. Outline Epidemiology Definitions Classification Other risk factors Associated With Development of Osteoporosis Classification Clinical Presentation

  • Upload
    others

  • View
    3

  • Download
    0

Embed Size (px)

Citation preview

  • 藥劑科實習生:黃中成指導老師:蘇蜂琪藥師

    2014.08.13

    Osteoporosis

  • Outline

    Epidemiology

    Definitions

    Classification

    Other risk factors Associated With Development of Osteoporosis Classification

    Clinical Presentation

    Diagnosis

    Bone remodeling model

    Pharmacologic Therapy

    Non-pharmacologic therapy

    Conclusion

  • EpidemiologyThe rapid increase in the global population of osteoporosis

    http://bone.la-dy.net/wiki/img_auth.php/6/68/072506.jpg

  • Definitions★

    Osteoporosis is a bone disorder characterized by

    low bone density , impaired bone architecture, and compromised bone strength predisposing a person to increased fracture risk.

    Normal Osteoporosis

  • Classification★Primary Osteoporosis:․Postmenopausal Osteoporosis:

    Estrogen deficiency during menopause increasesactivation of new osteoclasts to lose bone mass .

    ․Age-Related Osteoporosis:

    Because of PTH , calcium , and vitamin D deficiencies leading to accelerated bone turnover andreduced osteoblast formation.

  • Classification★Secondary Causes of Osteoporosis:‧Cushing syndrome

    ‧Hyperthyroidism

    ‧Primary hyperparathyroidism

    ‧Gastrointestinal disease

    ‧Drugs:․corticosteroids

    ․long-term anticonvulsant therapy

    ․Loop diuretics

  • Other risk factors Associated With development of Osteoporosis‧Asian

    ‧Small stature or Low Weight

    ‧Excessive alcohol intake or Cigarette smoking

    ‧ Early menopause or oophorectomy

  • Clinical Presentation

    Fracture(Spine、Hip、Wrist or Colles’ )

    Back pain

    Low activity

    Kyphosis or Lordosis

    Decrease height

    Spine

    Hip

    Wrist or Colles’

  • Diagnosis

    A WHO working group defined osteoporosis as the presence of bone mineral density(BMD) or a T-score.

    Measurement of central(hip and spine)BMD with dual-energy X-ray absorptiometry(DXA) is the gold standard for osteoporosis diagnosis.

  • DiagnosisT-score(SD)

    Bone density

    Normal Bone Mass

    Osteopenia

    Osteoporosis

  • Bone remodeling model

  • ‧Stimulating factor:‧PTH(intermittent)‧1,25(OH)2D3‧ T3 / T4‧TGF-β

    ‧Inhibiting factor:‧Glucocorticoid

    teriparatide

    Inhibiting factor:PTH(continuous)

    EstogenRaloxifen

    e

    DenosumabBisphosphates

    strontiu m

    ranelate

    Calcitonin

    TGF-β

    Cathepsin Kinhibitor

    Osteoprotegerin(OPG)

    1,25(OH)2D3High dose

    Antiresorptive agents

    Anabolic agents

  • Pharmacologic therapy★Bisphosphonates:

    Bisphosphonateshydroxyapatite

    Osteoclast

    combination

    Apoptosis

    Pharmacological mechanism of Bisphosphonates

    http://en.wikipedia.org/wiki/File:BisphosStruct.svg

  • Alendronate Risedronate Ibandronate Zoledronic acid Dosing 70mg Orally

    once weekly150mg Orally once monthly

    3mg IV infused over no less than 15 minutes. (once every 3 months)

    5mg IV infused over no less than 15 minutes. (once every 12 months)

    AdverseEffects

    ‧Esophagitis‧ONJ‧musculoskeletal

    pain

    ‧Esophagitis‧ONJ‧musculoskeletal

    pain

    ‧headache ‧arthralgiamusculoskeletal pain

    ‧Fevers ‧flulike‧symptoms ‧headache ‧arthralgia ‧musculoskeletal

    pain

  • Pharmacologic therapySERMs:

    Raloxifene

    RANKL inhibitor :

    Denosumab

    PTH:

    teriparatidestrontium ranelate

    Dosing 60 mg orally once daily

    60 mg subcutaneous once every 6 months

    20 mcg subcutaneously once daily for up to 2 years.

    2 gm Granules orally once daily

    Adverse Effects ‧venous thromboembolic disease(VTE)

    ‧ONJ‧serum Ca ↓‧Back pain

    ‧Dizzy ‧Cramp ‧Diarrhea

    ‧Headache ‧vomiting ‧Diarrhea ‧GI disease ‧VTE‧DRESS,SJS,TEN

    Contraindications Congestive heart failure

    Low serum Ca Osteosarcoma:‧Paget bone

    disease ‧unexplained

    alkalinephosphataseelevations

    ‧open epiphyses

    ‧transient ischemic attacks‧Antacid with

    cation ion ‧tetracycline ‧quinolone

  • Therapy of osteoporosis in men:Drugs Form of Drugs

    Alendronate(Fosamax®)

    Oral(tablet)Oral(liquid solution)

    Alendronate(Fosamax® Plus Vit D)

    Oral(tablet)

    Risedronate(Actonel®)

    Oral(tablet)

    Parathyroid Hormone(teriparatide / Ferteo®)

    Injection(IM‚SC)

    strontium ranelate(Protos®)

    Oral

  • Therapy of Postmenopausal Osteoporosis:Drugs Form of Drug

    Alendronate(Fosamax®)

    Oral(tablet)Oral(liquid solution)

    Alendronate(Fosamax® Plus Vit D) Oral(tablet)Ibandronate(Boniva®)

    Oral(tablet)Intravenous(IV)

    Risedronate(Actonel®)

    Oral(tablet)

    Zoledronic acid(Reclast®,Taiwan called Aclasta®)

    Intravenous(IV)

    SERMsRaloxifene(Evista®) Oral(tablet)

    Human monoclonal antibody for RANKL:

    Denosumab(Prolia®)

    Injection(SC)

    Parathyroid Hormone(teriparatide / Ferteo®)

    strontium ranelate(Protos®)

    Injection(IM‚SC)

    Oral

  • Non-pharmacologic therapy: Vitamin D 、PTH and Calcium

    PTH

    25-hydroxyvitamine D

    1,25-dihydroxyvitamine D

    Ca resorption

    Decrease resorption of P

    TH

    Ca resorption

    Glucocorticoids

    Increase excretion of Ca

    Blood —Low CalciumConcentration

    Calciumfor Resorption

  • Conclusion:★目前骨質疏鬆症治療的首選藥為雙磷酸鹽類,尤以口服劑

    型為優先。至於藥物合併使用方面,一般不建議併用二種抗 溶蝕藥品,如雙磷酸鹽類加Raloxifene的治療,因其會過度

    抑制骨骼汰舊率,導致骨骼太脆。而Alendronte合併 teriparatide對骨質密度無好處,且會降低teriparatide的同化

    效果。★想要維持良好的骨健康,從年輕時期就應養成良好生活型

    態,避免煙、酒和過量咖啡,均衡營養和規律運動,並多補 充鈣質,儲存骨本,使身體有較高的「尖峰骨量」。

    ★中年時期更須加強保護骨本,更年期婦女應儘早評估是否 宜補充女性荷爾蒙預防骨流失;年老時期則須加強防跌以防

    範生骨折。

  • Reference

    MICROMEDEX

    APPLIED THERAPEUYICS TENTH EDITION

    藥學雜誌 119版 69-74 骨質疏鬆症的治療

    Airiti 骨質疏鬆症的藥物治療

    行政院衛生署國民健康局-骨質疏鬆症-臨床治療指引

    臺安醫院

    醫藥專欄

    http://mypaper.pchome.com.tw/an8100shaow/post/13253484 07

    http://www.nhsdirect.wales.nhs.uk/encyclopaedia/c/article/co rticosteroid(drugs)

    http://www.scoopthelake.com/2014/04/29/risk-factors- osteoporosis-women/

    http://www.ultimatechirocare.com/cat-news-healthcare- naperville-woodridge-lisle-illinois-il/what-are-the-symptoms- of-osteoporosis/

    http://healthyliving88.com/osteoporosis/treatment-care/

    http://mypaper.pchome.com.tw/an8100shaow/post/1325348407http://mypaper.pchome.com.tw/an8100shaow/post/1325348407http://www.nhsdirect.wales.nhs.uk/encyclopaedia/c/article/corticosteroid(drugs)http://www.nhsdirect.wales.nhs.uk/encyclopaedia/c/article/corticosteroid(drugs)http://www.scoopthelake.com/2014/04/29/risk-factors-osteoporosis-women/http://www.scoopthelake.com/2014/04/29/risk-factors-osteoporosis-women/http://www.ultimatechirocare.com/cat-news-healthcare-naperville-woodridge-lisle-illinois-il/what-are-the-symptoms-of-osteoporosis/http://www.ultimatechirocare.com/cat-news-healthcare-naperville-woodridge-lisle-illinois-il/what-are-the-symptoms-of-osteoporosis/http://www.ultimatechirocare.com/cat-news-healthcare-naperville-woodridge-lisle-illinois-il/what-are-the-symptoms-of-osteoporosis/

  • OsteoporosisOutline�Epidemiology�DefinitionsClassificationClassificationOther risk factors Associated With development of OsteoporosisClinical PresentationDiagnosisDiagnosis�Bone remodeling model投影片編號 12Pharmacologic therapy投影片編號 14Pharmacologic therapyTherapy of osteoporosis in men:Therapy of Postmenopausal Osteoporosis:Non-pharmacologic therapy:�Vitamin D 、PTH and CalciumConclusion:Reference投影片編號 21